Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Allergic Conjunctivitis : News

Advertisement
Marketplace
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:October 2, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:October 2, 2009
... 2009. Fovea, founded in 2005, has three drugs undergoing clinical development, including a treatment for persistent allergic conjunctivitis in phase 2 trials, a retinal vein occlusion-induced macular edema treatment in phase 1 trials and a diabetic ...
Source:Drug Store News
Date:October 2, 2009
... It has a pipeline comprising three products in clinical development: eye drops for the treatment of persistent allergic conjunctivitis and diabetic macular oedema and an intravitreal formulation of a plasma kallikrein inhibitor for macular edema. ...
Source:PharmaExec.com
Date:October 1, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:October 1, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:October 1, 2009
... and particular species (like gerbils). Check out what you are feeding your dog and have her eyes checked for conjunctivitis or other eye problems that could cause excessive tearing. Wipe her tear-stained areas with hydrogen peroxide diluted in equal ...
Source:The Norman Transcript
Date:October 1, 2009
... fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal ...
Source:Drugs.com
Date:October 1, 2009
... fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal ...
Source:BioSpace
Date:October 1, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 30, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 30, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 29, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 29, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 29, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 29, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 29, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 25, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 25, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 25, 2009
... (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis. Metozolv ODT Metozolv ODT is a fasta 'dissolving formulation of metoclopramide for the shorta 'term treatment of ...
Source:Drugs.com
Date:September 24, 2009
Advertisement
Back to Top